989 related articles for article (PubMed ID: 9220055)
1. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
Bonapace CR; Mays DA
Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
[TBL] [Abstract][Full Text] [Related]
2. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
Clemett D; Markham A
Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
[TBL] [Abstract][Full Text] [Related]
3. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Hanauer S
Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
[TBL] [Abstract][Full Text] [Related]
4. Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease.
Small RE; Schraa CC
Pharmacotherapy; 1994; 14(4):385-98. PubMed ID: 7937276
[TBL] [Abstract][Full Text] [Related]
5. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
Segars LW; Gales BJ
Clin Pharm; 1992 Jun; 11(6):514-28. PubMed ID: 1600685
[TBL] [Abstract][Full Text] [Related]
6. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.
Prakash A; Markham A
Drugs; 1999 Mar; 57(3):383-408. PubMed ID: 10193690
[TBL] [Abstract][Full Text] [Related]
7. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
Modigliani R; Colombel JF; Dupas JL; Dapoigny M; Costil V; Veyrac M; Duclos B; Soulé JC; Gendre JP; Galmiche JP; Danne O; Cadiot G; Lamouliatte H; Belaïche J; Mary JY
Gastroenterology; 1996 Mar; 110(3):688-93. PubMed ID: 8608877
[TBL] [Abstract][Full Text] [Related]
8. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
9. Controversies with aminosalicylates in inflammatory bowel disease.
Lim WC; Hanauer SB
Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
[TBL] [Abstract][Full Text] [Related]
10. [5-Aminosalicylic acid in ulcerative colitis and Crohn's disease (author's transl)].
Maier K; Fischer C; Klotz U; Heinkel K
Dtsch Med Wochenschr; 1982 Jul; 107(29-30):1131-4. PubMed ID: 6123426
[TBL] [Abstract][Full Text] [Related]
11. Drug insight: aminosalicylates for the treatment of IBD.
Nielsen OH; Munck LK
Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
[TBL] [Abstract][Full Text] [Related]
12. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
Hanauer S; Schwartz J; Robinson M; Roufail W; Arora S; Cello J; Safdi M
Am J Gastroenterol; 1993 Aug; 88(8):1188-97. PubMed ID: 8338086
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic efficacy of 5-ASA molecules in idiopathic intestinal inflammatory diseases: critical review].
Van Gossum A
Acta Gastroenterol Belg; 1992; 55(5-6):462-71. PubMed ID: 1363167
[TBL] [Abstract][Full Text] [Related]
14. Transdermal nicotine for induction of remission in ulcerative colitis.
McGrath J; McDonald JW; Macdonald JK
Cochrane Database Syst Rev; 2004 Oct; (4):CD004722. PubMed ID: 15495126
[TBL] [Abstract][Full Text] [Related]
15. Medical management of patients with difficult-to-treat inflammatory bowel disease.
van Hogezand RA
Neth J Med; 1994 Aug; 45(2):55-9. PubMed ID: 7936006
[TBL] [Abstract][Full Text] [Related]
16. [5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease].
Moum B
Tidsskr Nor Laegeforen; 2003 Sep; 123(18):2565-7. PubMed ID: 14714043
[TBL] [Abstract][Full Text] [Related]
17. Oral 5-aminosalicylic acid preparations in treatment of inflammatory bowel disease. An update.
Martin F
Dig Dis Sci; 1987 Dec; 32(12 Suppl):57S-63S. PubMed ID: 2891469
[TBL] [Abstract][Full Text] [Related]
18. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease.
Thomson AB; Wright JP; Vatn M; Bailey RJ; Rachmilewitz D; Adler M; Wilson-Lynch KA
Aliment Pharmacol Ther; 1995 Dec; 9(6):673-83. PubMed ID: 8824656
[TBL] [Abstract][Full Text] [Related]
19. Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis?
Nakshabendi IM; Duncan A; Russell RI
Postgrad Med J; 1992 Mar; 68(797):189-91. PubMed ID: 1350343
[TBL] [Abstract][Full Text] [Related]
20. [Current therapeutic possibilities in chronic inflammatory intestinal diseases].
Schölmerich J
Praxis (Bern 1994); 1995 Jan; 84(2):29-33. PubMed ID: 7839043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
